市場調查報告書
商品編碼
997536

多囊性卵巢症候群(PCOS)治療的全球市場

Polycystic Ovary Syndrome (PCOS) Treatment

出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 282 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球多囊性卵巢症候群(PCOS)治療的市場規模,預計在分析期間(2020年∼2027年)將以3.5%的年複合成長率增長,從2020年的36億美元,到2027年達到46億美元。

本報告所分析的市場區隔之一的口服避孕藥部門,分析期間中預計將以5%的年複合成長率增長,達到12億美元。

本報告提供全球多囊性卵巢症候群(PCOS)治療市場的相關調查,提供市場佔有率,Covid-19的影響,趨勢和成長要素,各地區的市場分析,競爭情形,主要企業的簡介等資訊。

調查對象企業範例

  • Addex Therapeutics
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Crinetics Pharmaceuticals, Inc.
  • Ferring Pharmaceuticals, Inc.
  • JSC BIOCAD
  • Merck KgaA
  • Teva Pharmaceutical Industries Ltd.

目錄

I. 調查手法

II. 摘要整理

  • 市場概要
    • 影響者市場洞察
    • 全球市場的軌跡
    • Covid-19的影響與即將到來的全球景氣衰退
  • 主要企業
  • 趨勢與推動要素
  • 全球市場預測

III. 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 南美
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他南美國家
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東
  • 非洲

IV. 競爭

  • 企業簡介:42公司
目錄
Product Code: MCP14056

Abstract:

Global Polycystic Ovary Syndrome (PCOS) Treatment Market to Reach $4.6 Billion by 2027

Amid the COVID-19 crisis, the global market for Polycystic Ovary Syndrome (PCOS) Treatment estimated at US$3.6 Billion in the year 2020, is projected to reach a revised size of US$4.6 Billion by 2027, growing at a CAGR of 3.5% over the analysis period 2020-2027. Oral Contraceptives, one of the segments analyzed in the report, is projected to record a 5% CAGR and reach US$1.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Antiandrogen segment is readjusted to a revised 3.7% CAGR for the next 7-year period.

The U.S. Market is Estimated at $981.1 Million, While China is Forecast to Grow at 6.4% CAGR

The Polycystic Ovary Syndrome (PCOS) Treatment market in the U.S. is estimated at US$981.1 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$983.7 Million by the year 2027 trailing a CAGR of 6.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1% and 2.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.

Insulin-Sensitizing Agents Segment to Record 3.1% CAGR

In the global Insulin-Sensitizing Agents segment, USA, Canada, Japan, China and Europe will drive the 2.6% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$924 Million in the year 2020 will reach a projected size of US$1.1 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$646 Million by the year 2027, while Latin America will expand at a 3.9% CAGR through the analysis period.

Select Competitors (Total 42 Featured) -

  • Addex Therapeutics
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Crinetics Pharmaceuticals, Inc.
  • Ferring Pharmaceuticals, Inc.
  • JSC BIOCAD
  • Merck KgaA
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Oral Contraceptives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Oral Contraceptives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Oral Contraceptives by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Antiandrogen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Antiandrogen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Antiandrogen by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Insulin-Sensitizing Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Insulin-Sensitizing Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Insulin-Sensitizing Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Antidepressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Anti-Obesity Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Anti-Obesity Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Anti-Obesity Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Ovarian Wedge Resection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Ovarian Wedge Resection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Ovarian Wedge Resection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Laparoscopic Ovarian Drilling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Laparoscopic Ovarian Drilling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Laparoscopic Ovarian Drilling by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 25: USA Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 26: USA Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 27: USA 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown of Value Sales for Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents for the Years 2012, 2020 & 2027
    • TABLE 28: USA Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 29: USA Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 30: USA 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Percentage Breakdown of Value Sales for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 31: Canada Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 32: Canada Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 33: Canada 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown of Value Sales for Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents for the Years 2012, 2020 & 2027
    • TABLE 34: Canada Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 35: Canada Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 36: Canada 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Percentage Breakdown of Value Sales for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 37: Japan Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 38: Japan Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 39: Japan 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown of Value Sales for Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents for the Years 2012, 2020 & 2027
    • TABLE 40: Japan Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 41: Japan Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: Japan 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Percentage Breakdown of Value Sales for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 43: China Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: China Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 45: China 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown of Value Sales for Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents for the Years 2012, 2020 & 2027
    • TABLE 46: China Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 47: China Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 48: China 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Percentage Breakdown of Value Sales for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 49: Europe Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 50: Europe Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 51: Europe 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 52: Europe Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Europe Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 54: Europe 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown of Value Sales for Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents for the Years 2012, 2020 & 2027
    • TABLE 55: Europe Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Europe Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 57: Europe 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Percentage Breakdown of Value Sales for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 58: France Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 59: France Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 60: France 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown of Value Sales for Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents for the Years 2012, 2020 & 2027
    • TABLE 61: France Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 62: France Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 63: France 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Percentage Breakdown of Value Sales for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 64: Germany Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Germany Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 66: Germany 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown of Value Sales for Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents for the Years 2012, 2020 & 2027
    • TABLE 67: Germany Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Germany Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 69: Germany 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Percentage Breakdown of Value Sales for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 70: Italy Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 71: Italy Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 72: Italy 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown of Value Sales for Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents for the Years 2012, 2020 & 2027
    • TABLE 73: Italy Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Italy Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 75: Italy 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Percentage Breakdown of Value Sales for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 76: UK Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 77: UK Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 78: UK 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown of Value Sales for Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents for the Years 2012, 2020 & 2027
    • TABLE 79: UK Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 80: UK Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 81: UK 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Percentage Breakdown of Value Sales for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
  • SPAIN
    • TABLE 82: Spain Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Spain Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 84: Spain 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown of Value Sales for Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents for the Years 2012, 2020 & 2027
    • TABLE 85: Spain Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Spain Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 87: Spain 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Percentage Breakdown of Value Sales for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
  • RUSSIA
    • TABLE 88: Russia Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Russia Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 90: Russia 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown of Value Sales for Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents for the Years 2012, 2020 & 2027
    • TABLE 91: Russia Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Russia Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 93: Russia 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Percentage Breakdown of Value Sales for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 94: Rest of Europe Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Rest of Europe Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 96: Rest of Europe 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown of Value Sales for Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents for the Years 2012, 2020 & 2027
    • TABLE 97: Rest of Europe Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Rest of Europe Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 99: Rest of Europe 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Percentage Breakdown of Value Sales for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 100: Asia-Pacific Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 101: Asia-Pacific Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 102: Asia-Pacific 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
    • TABLE 103: Asia-Pacific Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Asia-Pacific Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 105: Asia-Pacific 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown of Value Sales for Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents for the Years 2012, 2020 & 2027
    • TABLE 106: Asia-Pacific Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Asia-Pacific Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 108: Asia-Pacific 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Percentage Breakdown of Value Sales for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
  • AUSTRALIA
    • TABLE 109: Australia Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 110: Australia Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 111: Australia 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown of Value Sales for Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents for the Years 2012, 2020 & 2027
    • TABLE 112: Australia Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 113: Australia Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 114: Australia 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Percentage Breakdown of Value Sales for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
  • INDIA
    • TABLE 115: India Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 116: India Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 117: India 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown of Value Sales for Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents for the Years 2012, 2020 & 2027
    • TABLE 118: India Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 119: India Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 120: India 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Percentage Breakdown of Value Sales for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
  • SOUTH KOREA
    • TABLE 121: South Korea Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 122: South Korea Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 123: South Korea 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown of Value Sales for Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents for the Years 2012, 2020 & 2027
    • TABLE 124: South Korea Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 125: South Korea Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 126: South Korea 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Percentage Breakdown of Value Sales for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 127: Rest of Asia-Pacific Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 128: Rest of Asia-Pacific Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 129: Rest of Asia-Pacific 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown of Value Sales for Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents for the Years 2012, 2020 & 2027
    • TABLE 130: Rest of Asia-Pacific Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 131: Rest of Asia-Pacific Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 132: Rest of Asia-Pacific 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Percentage Breakdown of Value Sales for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
  • LATIN AMERICA
    • TABLE 133: Latin America Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 134: Latin America Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 135: Latin America 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
    • TABLE 136: Latin America Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 137: Latin America Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 138: Latin America 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown of Value Sales for Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents for the Years 2012, 2020 & 2027
    • TABLE 139: Latin America Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 140: Latin America Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 141: Latin America 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Percentage Breakdown of Value Sales for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
  • ARGENTINA
    • TABLE 142: Argentina Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 143: Argentina Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 144: Argentina 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown of Value Sales for Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents for the Years 2012, 2020 & 2027
    • TABLE 145: Argentina Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 146: Argentina Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 147: Argentina 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Percentage Breakdown of Value Sales for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
  • BRAZIL
    • TABLE 148: Brazil Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 149: Brazil Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 150: Brazil 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown of Value Sales for Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents for the Years 2012, 2020 & 2027
    • TABLE 151: Brazil Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 152: Brazil Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 153: Brazil 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Percentage Breakdown of Value Sales for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
  • MEXICO
    • TABLE 154: Mexico Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 155: Mexico Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 156: Mexico 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown of Value Sales for Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents for the Years 2012, 2020 & 2027
    • TABLE 157: Mexico Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 158: Mexico Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 159: Mexico 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Percentage Breakdown of Value Sales for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
  • REST OF LATIN AMERICA
    • TABLE 160: Rest of Latin America Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 161: Rest of Latin America Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 162: Rest of Latin America 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown of Value Sales for Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents for the Years 2012, 2020 & 2027
    • TABLE 163: Rest of Latin America Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 164: Rest of Latin America Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 165: Rest of Latin America 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Percentage Breakdown of Value Sales for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
  • MIDDLE EAST
    • TABLE 166: Middle East Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 167: Middle East Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 168: Middle East 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
    • TABLE 169: Middle East Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 170: Middle East Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 171: Middle East 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown of Value Sales for Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents for the Years 2012, 2020 & 2027
    • TABLE 172: Middle East Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 173: Middle East Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 174: Middle East 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Percentage Breakdown of Value Sales for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
  • IRAN
    • TABLE 175: Iran Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 176: Iran Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 177: Iran 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown of Value Sales for Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents for the Years 2012, 2020 & 2027
    • TABLE 178: Iran Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 179: Iran Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 180: Iran 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Percentage Breakdown of Value Sales for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
  • ISRAEL
    • TABLE 181: Israel Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 182: Israel Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 183: Israel 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown of Value Sales for Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents for the Years 2012, 2020 & 2027
    • TABLE 184: Israel Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 185: Israel Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 186: Israel 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Percentage Breakdown of Value Sales for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
  • SAUDI ARABIA
    • TABLE 187: Saudi Arabia Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 188: Saudi Arabia Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 189: Saudi Arabia 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown of Value Sales for Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents for the Years 2012, 2020 & 2027
    • TABLE 190: Saudi Arabia Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 191: Saudi Arabia Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 192: Saudi Arabia 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Percentage Breakdown of Value Sales for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 193: UAE Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 194: UAE Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 195: UAE 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown of Value Sales for Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents for the Years 2012, 2020 & 2027
    • TABLE 196: UAE Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 197: UAE Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 198: UAE 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Percentage Breakdown of Value Sales for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
  • REST OF MIDDLE EAST
    • TABLE 199: Rest of Middle East Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 200: Rest of Middle East Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 201: Rest of Middle East 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown of Value Sales for Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents for the Years 2012, 2020 & 2027
    • TABLE 202: Rest of Middle East Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 203: Rest of Middle East Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 204: Rest of Middle East 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Percentage Breakdown of Value Sales for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027
  • AFRICA
    • TABLE 205: Africa Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 206: Africa Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 207: Africa 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class - Percentage Breakdown of Value Sales for Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents for the Years 2012, 2020 & 2027
    • TABLE 208: Africa Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 209: Africa Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 210: Africa 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type - Percentage Breakdown of Value Sales for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 42